Skip to main content
Vercise Genus P8 IPG and lead in operating room.

Deep Brain Stimulation System

Vercise Genus Batteries

The broadest IPG portfolio in the market

Tailor a deep brain stimulation (DBS) system specific to your workflow and patient’s needs. Boston Scientific’s DBS System includes 5 thin, contoured ImageReady™ MR Conditional rechargeable and non-rechargeable Implantable Pulse Generators (IPGs), the most therapy options*, and personalized therapy with Image Guided Programming.

To get answers to your questions and additional information on Boston Scientific’s DBS System, contact a DBS sales representative.

Proven battery technology

With more than 25,000 patients implanted worldwide and 10 years of proven performance1, Boston Scientific has a battery you can depend on.

Vercise Genus IPGs P8, P16, P32, R16 and R32.


  • Small, contoured design for patient comfort
  • Vercise Genus P8 is the only directional single-channel primary cell
  • Vercise Genus P8 has over 50% more battery capacity than Activa SC3


  • 30 days of recharge-free therapy2
  • Warrantied for 15 years
  • Reduce replacement surgeries and the potential for infections

Switch to the Vercise Genus DBS System with confidence

The Vercise™ Adapters are a battery conversion system designed by Boston Scientific for DBS patients with Medtronic® or Abbott® technology. Switching from an existing IPG to a Boston Scientific IPG has been shown to improve patient symptoms or reduce side effects without the need to change a patient’s leads.

Vercise Genus battery adapter.

The Vercise M8 Adaptor is MR Conditional, maintaining your patient’s access to this important diagnostic imaging tool should they need it in the future.

68% of patients

see an improvement in systems or reduction in side effects by switching to a Boston scientific device (n=22)4

Boston Scientific IPGs powered by MICC

Manage your patient’s evolving needs. Precisely shape and steer stimulation where it’s needed most and leverage more programming flexibility by combining the power of MICC with the Vercise™ Cartesia™ Directional Lead.

Vercise Cartesia lead with Multiple Independent Current Control.

If you are a patient looking for more information on DBS, visit

* Information for competitive devices excerpted from the literature published by Medtronic (M982261A015 Rev A, M017563C002 Rev A, M939241A051 Rev A, M927170A073 Rev A, M017562C002 Rev A, M982097A013 Rev A) and Abbott (ARTEN600150429 - B, ARTEN600102238 - A, ARTEN600266398 -A), and Schüpbach, Michael & Chabardes, Stephan & Matthies, Cordula & Pollo, Claudio & Steigerwald, Frank & Timmermann, Lars & Vandewalle, Veerle & Volkmann, Jens & Schuurman, P.. (2017). Directional leads for deep brain stimulation: Opportunities and challenges. Movement Disorders. 32. 10.1002/mds.27096.

Steffen, J. K., Reker, P., Mennicken, F. K., Dembek, T. A., Dafsari, H. S., Fink, G. R., Visser-Vandewalle, V., & Barbe, M. T. (2020). Bipolar Directional Deep Brain Stimulation in Essential and Parkinsonian Tremor. Neuromodulation: Technology at the Neural Interface, 23(4), 543–549. DOI: 10.1111/ner.13109

Reker, P., Dembek, T. A., Becker, J., Visser-Vandewalle, V., & Timmermann, L. (2016). Directional deep brain stimulation: A case of avoiding dysarthria with bipolar directional current steering. Parkinsonism & Related Disorders, 31, 156-158.

Kirsch, A. D., Hassin-Baer, S., Matthies, C., Volkmann, J., & Steigerwald, F. (2018). Anodic versus cathodic neurostimulation of the subthalamic nucleus: A randomized-controlled study of acute clinical effects. Parkinsonism & Related Disorders, 55, 61-67.

Boston Scientific (Vercise ™ Neural Navigator 5 Software Programming Manual MP92736308-01).

 1. Boston Scientific data on file.

2. Yu X, et al. (2013). Characterizing rechargeable IPG charge cycle time in DBS. North American Neuromodulation Society (NANS) 2013.

3. Information for competitive devices accessed from; accessed on Oct 5, 2023, and Boston Scientific data on file.

4. Ojukwu DI, Wang AR, Hornbeck TS, Lim EA, Sharrard J, Dhall R, Buch VP, Halpern CH. Conversion to Hybrid Deep Brain Stimulation System to Enable Multi-Contact Fractionation Can be Therapeutic. Mov Disord. 2022 Apr 7. doi: 10.1002/mds.29007. Epub ahead of print. PMID: 35393689.

The Boston Scientific Vercise™ PC, Vercise Gevia™, Vercise Genus™ Deep Brain Stimulation Systems are indicated for use in: 

-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication. 
-Bilateral stimulation of the internal globus pallidus (GPi) as an adjunctive therapy in reducing some of the symptoms of advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.  
-Unilateral thalamic stimulation of the ventral intermediate nucleus (VIM) is indicated for the suppression of tremor in the upper extremity. The system is intended for use in patients who are diagnosed with essential tremor or parkinsonian tremor not adequately controlled by medications and where the tremor constitutes a significant functional disability. 

The Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in:

-Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson’s disease (PD) that are not adequately controlled with medication.

The Boston Scientific Deep Brain Stimulation (DBS) Systems or any of its components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with the Boston Scientific DBS System has not been established, patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Patients implanted with Boston Scientific DBS System without ImageReady™ MRI Technology should not be exposed to Magnetic Resonance Imaging (MRI). Patients implanted with Vercise Gevia or Vercise Genus or Vercise Genus Mixed System with M8 Adapter or Vercise DBS Lead-Only System (before Stimulator is implanted) with ImageReady MRI Technology are Full Body MR Conditional only when exposed to the MRI environment under the specific conditions defined in ImageReady MRI Guidelines for Boston Scientific DBS Systems. Assess patients for the risks of depression and suicide. This assessment should consider both the risk of depression and suicide as well as the potential clinical benefits of DBS therapy. Monitor patients for new or worsening symptoms of depression, suicidal thoughts or behaviors, or changes in mood or impulse control and manage appropriately.  Refer to the Instructions for Use provided with the Boston Scientific DBS Systems or for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.